INTRODUCTION
============

Ischemia/reperfusion (I/R) injury is the exacerbation of tissue damage upon reestablishment of circulation after a period of ischemia. I/R injury is considered a major contributor to tissue damage in multiple clinical situations such as myocardial infarction, stroke, and organ transplantation. In many clinical settings, the duration of ischemia is beyond control, and preventive and therapeutical measures are required to reduce the extent of I/R injury. Unfortunately, current treatment is primarily supportive. The pathophysiology of I/R injury is multifactorial and only partially understood. However, the general local reaction to reperfusion is thought to involve an inflammatory response that leads to tissue damage. In the quest for new therapeutical options for renal I/R injury, stem cells have come into play. With their multipotent immune modulating properties they hold promise to lead to improvement in the treatment of renal I/R injury.

PATHOPHYSIOLOGY OF ISCHEMIA/REPERFUSION INJURY
==============================================

Although there may be differences in the exact pathophysiological mechanisms of I/R injury between different organs, some processes appear to play a universal role ([@B28]). The endothelium and microvasculature are very sensitive to hypoxia and easily affected in I/R injury. Upon reperfusion, the vascular endothelial cell lining can undergo swelling which may lead to narrowing of the vascular lumen ([@B88]; [@B54]). Moreover, vasorelaxation can be impaired, together contributing to the no-reflow phenomenon ([@B55]). Endothelial injury can increase microvascular permeability which may lead to inflammatory cell recruitment into the diseased organ. There have been many reports of invading granulocytes, monocytes, dendritic cells (DCs), and lymphocytes after reperfusion ([@B84]; [@B9]; [@B16], [@B15]; [@B18]).

Together with leukocytes, platelets can be activated by injured endothelium. In myocardial infarction, platelets mediate thrombotic occlusion and increase damage by contributing to the no-reflow phenomenon ([@B32]). However, platelets are also able to invade the tissue ([@B103]). This is essential since platelets can contribute to the inflammatory response through release of cytokines, chemokines, and growth factors from their granules ([@B81]; [@B56]; [@B93]). In fact, platelets have been suggested to be involved in the inflammatory response of I/R injury in various organs. They are able to roll and adhere to post-reperfusion endothelium in a P-selectin-dependent mechanism ([@B61]; [@B85]; [@B43]; [@B2]). In mouse myocardial tissue, the first activated platelets are present within minutes after reperfusion ([@B106]), and then accumulate in the infarcted myocardium ([@B57]).

The ensuing inflammatory response is considered to exacerbate damage. Both the innate and the adaptive immune system can be activated after reperfusion. Activation of the innate immune system is probably mediated via pattern-recognition receptors such as toll-like receptors that recognize their endogenous ligands that are released upon tissue damage ([@B11]). Besides, the complement system is part of the humoral immune response and can play a role both as first line innate defense, but may also contribute to the adaptive immune response ([@B26]). In many animal experiments a role for (terminal) complement activation in I/R injury has been suggested ([@B114]; [@B75]; [@B17]; [@B113]; [@B110]), although recent experiments doubt the involvement of the complement system itself in the initiation of injury ([@B101]). The role of complement activation in human I/R injury is even more complex. While in human myocardial I/R injury a role of complement activation was suggested ([@B108]; [@B4]), the diverse intervention studies using anti-complement therapy did not lead to major improvements ([@B34]; [@B60]; [@B51]; [@B102]; [@B92]).

Ischemia-related metabolic adaptations and dysregulated mitochondrial homeostasis are thought to result in substantial release of reactive oxygen and nitrogen species (RONS) upon reintroduction of oxygen. The RONS overload can overwhelm the endogenous antioxidant system, resulting in oxidative damage. This may trigger secondary processes and contribute to the pro-inflammatory response upon reperfusion ([@B12]; [@B100]; [@B33]; [@B63]). Numerous animal studies clearly demonstrated that antioxidant therapy ameliorates I/R injury ([@B103]; [@B109]; [@B48]). Despite these findings, studies in humans consistently fail to show any clinically relevant effect ([@B49]; [@B6]; [@B27]; [@B109]; [@B89]). The basis for this discrepancy between human and animal studies is still unclear, yet it may suggest that the contribution of RONS to I/R injury in humans is less than commonly thought.

Ultimately, when I/R injury to the cell is severe, various programs of cell death can be activated. There are three major forms of cell death: necrosis, apoptosis, and autophagy. Besides acute cell death during and directly after the ischemic period, cell death continues for several days following reperfusion. All three types of cell death can contribute to the continued loss of cells for days and even weeks in the reperfused tissue ([@B111], [@B112]). Autophagy during the ischemic episode appears to keep cells viable and might play a protective role. However, it is suggested that activation of autophagy after reperfusion is detrimental ([@B62]; [@B37]).

ISCHEMIA/REPERFUSION INJURY IN KIDNEY TRANSPLANTATION
=====================================================

Ischemia/reperfusion injury is an inevitable consequence of kidney transplantation. Graft survival for living unrelated donation is superior compared to grafts from brain dead and cardiac dead donors, although the average human leukocyte antigen (HLA) matching is worse ([@B91]). Therefore, the poor graft survival of deceased donor kidneys cannot be exclusively attributed to differences in immunogenicity. I/R injury can induce delayed graft function and has a major influence on graft function and survival ([@B107]).

Inflammation is regarded the crucial event in the development of tissue injury and graft dysfunction in renal I/R injury. Many individual factors, such as cytokines and complement have been identified to be involved in the inflammatory response. However, intervention studies aiming at specific inhibition of a single factor have generally shown disappointing results ([@B75]; [@B9]). Cooperation, redundancy, and interactions play a role and mechanisms appear to be more complex than previously thought. Pharmacological inhibition of the entire inflammatory cascade would appear a logical intervention, however, the negative side effects appear larger than the anticipated beneficial effects ([@B64]).

ISCHEMIA/REPERFUSION INJURY: LONG-TERM IMPACT
=============================================

Although short-term results of kidney transplantation are excellent, 5 year graft loss can be up to 30% in older recipients ([@B42]). Protocol biopsies obtained in the first years after transplantation have shown interstitial fibrosis/tubular atrophy (IF/TA). This finding has been correlated with later allograft dysfunction and loss ([@B69]; [@B76]). Both allogen dependent and independent factors determine IF/TA. I/R injury is an important non-allogeneic factor and the duration of the cold ischemic period is directly correlated to delayed graft function and even allograft failure ([@B73]; [@B83]). I/R injury itself, without allogeneic transplantation, has been shown to cause interstitial fibrosis and glomerulosclerosis in experimental models ([@B99]; [@B39]; [@B5]; **Figure [1](#F1){ref-type="fig"}**).

![**Male, 8-week-old Bl6 mice underwent bilateral (warm) renal ischemia for 25 min by clamping of the renal artery and vein.** Long-term structural damage and fibrosis were assessed. I/R injury induced severe patchy renal fibrosis three weeks after ischemia, although kidney function partially recovered. Sirius red staining shows **(A)** normal mouse kidney and **(B)** severe fibrosis 3 weeks after the mouse underwent 25 min of warm renal I/R injury (Representative images, unpublished data).](fimmu-03-00162-g001){#F1}

RENAL REPAIR
============

In recent years, it has become clear that in response to kidney injury not only fibrotic repair but also restoration of damaged kidney tissue can occur. This has been best established for acute kidney injury, where surviving resident tubular epithelial cells dedifferentiate and subsequently re-enter the cell cycle to replace the necrotic tubular epithelium. Dedifferentiated cells outside the injured kidney may also migrate to the site of injury within the kidney. Kidney biopsies in male recipients of a female donor kidney with acute tubular necrosis showed presence of the male Y chromosome in renal tubular cells. No Y chromosome staining was seen in patients without acute tubular necrosis. This provides evidence that extra-renal cells participate in renal regeneration ([@B79]; [@B35]).

The call for better treatment strategies for I/R injury has directed research toward more encompassing cellular-based therapies, particularly aimed at the use of stem cells. The multi-factorial pathophysiology of I/R injury makes a pharmacological agent that has a single mechanistic target less likely to be therapeutically effective. In contrast, stem cells are versatile, and able to target a whole cascade of repair mechanisms simultaneously and successively, thereby improving organ protection and repair.

MESENCHYMAL STROMAL CELLS
=========================

Of all bone marrow (bm)-derived cells, mesenchymal stromal cells (MSCs) hold special promise in attenuating kidney injury, since nephrons are largely of mesenchymal origin and stromal cells are of crucial importance for signaling leading to differentiation of both nephrons and collecting ducts. MSCs are characterized by three main criteria: (1) The ability to differentiate into osteoblasts, adipocytes, and chondroblasts *in vitro*, (2) the expression of surface makers CD73, CD90, and CD105, and lack of expression of haematopoietic markers including CD34 and CD45, and (3) plastic adherence in culture ([@B23]).

Mesenchymal stromal cells have the ability to secrete numerous growth factors and cytokines that collectively stimulate mitogenesis, inhibit apoptosis, and modulate immune responses. They can alter cytokine secretion profiles of T cells ([@B45]), DCs, and natural killer cells to induce a more anti-inflammatory or tolerant phenotype ([@B1]; [@B86]). These immune modulating effects could be achieved both with autologous and allogeneic MSCs.

An important aspect of the effect of MSCs is their ability to home to areas of injury or inflammation. Exogenously administered MSCs can engraft into various injured structures in the kidney ([@B71]; [@B38]; [@B104]). Recently, studies have shed light on the exact factors that facilitate homing of MSCs. Amid them, CD44 and hyaluronic acid interactions, and stromal-derived factor-1 (SDF-1) and CXCR4 interactions may be crucial in recruiting exogenous MSCs to injured renal ([@B95]; [@B38]).

SOURCES OF MSCs
===============

While initially isolated from the bm, MSCs have now been identified within most tissues and are thought to represent a perivascular cell population involved in normal tissue homeostasis ([@B13]). Indeed, MSCs have been isolated from adipose tissue, umbilical cord (uc) blood, placenta, and various organs ([@B115]; [@B66]; [@B98]; [@B14]; [@B40]). Recently, MSCs have also been isolated from the human and mouse kidney. In mice these cells were extensively compared to bmMSCs ([@B77]). Transcriptome and immunophenotype analysis of the renal MSC-like populations supported strong congruence with bmMSCs. Future studies need to elucidate whether regeneration and functional repair can be enhanced via the resident renal stem cells. In the meantime, bmMSCs are the best characterized population and currently more than 200 clinical trials are ongoing using bmMSCs^[1](#fn01){ref-type="fn"}^

MSCs AMELIORATE RENAL ISCHEMIA/REPERFUSION INJURY *IN VIVO*
===========================================================

Although MSCs most probably do not replace damaged cells, evidence on beneficial effects of MSCs in renal I/R injury is accumulating in animal experiments. Intravenous injection of bm-derived lineage-negative pluripotent cells after experimental renal I/R significantly attenuated the creatinine rise ([@B25]). Peripherally administered purified MSCs significantly attenuated functional and histological damage ([@B30]). Even when administered 24 h or later after I/R injury, MSCs still were able to ameliorate damage and fibrosis ([@B50]; [@B94]; [@B24]). In experimental renal allograft transplantation MSCs decreased inflammation ([@B36]).

Different studies have reported beneficial effects of human MSCs on acute repair in the kidney ([@B65]). The therapeutic potential of human bmMSCs was studied in immunodeficient NOD-SCID mice. Infused human bmMSCs reduced renal cell apoptosis and increased proliferation after cisplatin-induced acute renal failure. bmMSCs also preserved the integrity of the tubular epithelium and peritubular vessels, and prolonged survival ([@B67]). In search for new sources of MSCs for renal repair, human ucMSCs were shown to ameliorate both renal dysfunction and tubular cell injury, and prolong survival in cisplatin-induced acute kidney injury ([@B68]).

The mechanism of MSC-induced kidney repair has been the subject of numerous studies. There is growing evidence that the process of transdifferentiation is probably not relevant to renal repair *in vivo*. The primary means of these cells most likely involve paracrine and endocrine effects; including mitogenic, anti-apoptotic, anti-inflammatory, antifibrotic, and angiogenic influences **Figure [2](#F2){ref-type="fig"};** [@B71]). The factors that mediate the paracrine effects are obviously of great interest. Several factors that are abundant in MSC-conditioned medium have been mentioned ([@B96]). Recently, it was suggested that microvesicles released from MSCs may account for this paracrine mechanism. Administration of isolated microvesicles from human MSCs indeed protected rats from acute ischemic kidney injury ([@B8]; [@B31]).

![**MSCs diminish damage and induce repair.** Schematic illustration of the paracrine effects of MSCs on the kidney. While stimulating repair by mitogenic and angiogenic effects, MSCs inhibit ongoing inflammation, apoptosis and later fibrosis of injured tissue.](fimmu-03-00162-g002){#F2}

CLINICAL APPLICATIONS OF MSCs IN RENAL DISEASE
==============================================

There are only limited clinical data about MSC therapy in renal disease. The first safety and feasibility data of autologous MSC administration in the week after kidney transplantation were published in 2011 ([@B78]). Although data are limited to two patients, MSC infusion appeared feasible and restricted memory T cell expansion while enlarging Treg population. However, both patients showed transient increase in serum creatinine levels within 2 weeks after cell infusion that might be related to intragraft recruitment of granulocytes, suggesting that timing of infusion is of particular importance ([@B74]; [@B29]; [@B50]). This is probably related to the necessity for the appropriate micro-environment to allow MSCs to acquire their anti-inflammatory properties. In addition, in a recent study the use of autologous MSCs resulted in lower incidence of acute rejection, decreased risk of opportunistic infection and better estimated renal function at 1 year compared with anti-IL-2 receptor antibody as induction therapy ([@B90]). In our clinical trial we investigate safety and feasibility of autologous bmMSC treatment in patients with subclinical rejection and/or IF/TA in the renal biopsy at 4 weeks or 6 months after renal transplantation (Clinical trials NCT00734396). Hereby we expect to provide additional information about the importance of timing in the transplant setting.

AUTOLOGOUS VERSUS ALLOGENEIC MSCs
---------------------------------

Until now, most studies have focused on the use of autologous cells since allogeneic cell transplantation may promote allograft rejection and possibly sensitization ([@B70]; [@B87]). However, autologous MSCs also have disadvantages. The cells need weeks of culture and a concern for the use of autologous MSCs includes their potential dysfunction due to the underlying disease. Few studies have reported influence of renal failure on MSC behavior. In mice, functional incompetence of MSCs was reported under uremic conditions ([@B72]). In addition, in human MSCs it was shown that uremic serum induced an osteoblast-like phenotype in MSCs accompanied by matrix remodeling and calcification ([@B44]). In contrast, it was recently shown that human adipose tissue-derived MSCs are not affected by renal disease ([@B82]).

MSC NUMBER, ROUTE OF ADMINISTRATION, AND INTERACTION WITH IMMUNOSUPPRESSIVES
----------------------------------------------------------------------------

Alongside the cell source, the number of MSCs and the timing of administration are critical. In most clinical trials doses of 0.4 to 10 × 10^6^/kg body weight were used ([@B52]; [@B53]; [@B59]). However, no clear correlations have been made between cell dose and clinical effect. Dose escalation studies to monitor safety and efficacy are one of the major objectives for future studies of MSCs.

Mesenchymal stromal cells have been administered intravenously in most human trials. Other possible successful routes of administration include intra-arterial or intra-renal infusion ([@B47][@B46]; [@B21]). An advantage of these routes may be the direct administration at the place of injury, whereas disadvantages include the complexity and possible side effects such as obstruction of capillaries. To date, there are no reports of these treatment modalities in humans.

Current immunosuppressive drugs cannot be withheld from patients receiving MSC treatment after renal transplantation. Therefore, it is of importance that an optimal concurrent immunosuppressive regimen is chosen in which drugs have no negative impact on MSC function and vice versa. So far, this interaction has mainly been assessed by *in vitro* studies ([@B58]; [@B80]) and future studies are needed to elucidate their interaction with concurrent immunosuppression *in vivo* in order to facilitate successful translation to the clinic.

POSSIBLE HURDLES OF MSC TREATMENT
---------------------------------

Although cell therapy with MSCs holds enormous promise for the treatment of many diseases, unwanted side effects of MSC infusions must be assessed with the greatest care. Experimental studies have demonstrated maldifferentiation after injecting MSCs directly into damaged tissue ([@B7]; [@B46]). In addition, MSCs may adopt and unwanted, myofibroblast-like phenotype after administration ([@B105]; [@B20]). Another important concern is that MSCs may differentiate into neoplastic cells or may cause promotion of tumor cell growth ([@B22]; [@B41]; [@B97]), although an increased risk of tumor formation has never been confirmed in humans ([@B10]). Currently, more than 2000 patients have been treated with allogeneic or autologous MSCs worldwide for a variety of diseases and so far no major side effects have been reported. However, still little is known about long-term side effects.

SUMMARY
=======

The pathophysiology of I/R injury is complex and characterized by inflammation, leading to tissue injury and graft dysfunction. Given current shortage of donor organs and usage of marginal donor kidneys for transplantation, novel treatment options to minimize renal I/R injury are urgently needed. Recent developments in stem cell research and derived clinical stem cell therapies have given reason to believe that such cell-based treatments will become generally available in the near future. Although substantial additional time for the maturation of these therapies for routine clinical use is needed, the first steps of MSC-based therapeutic strategies in the treatment of I/R injury have been taken.
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